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Objective: To systematically review the effectiveness and safety of intravascular temperature management (IVTM) 
versus surface cooling methods (SCM) for induced hypothermia (IH).  
Methods: Systematic review and meta-analysis. English-language PubMed, Embase and the Cochrane Database of 
Systematic Reviews were searched on May 27, 2019. The quality of included observational studies was graded using the 
Newcastle-Ottawa Quality Assessment tool. The quality of  included randomized trials was evaluated using the Cochrane 
Collaboration’s risk of bias tool. Random effects modeling was used to calculate risk differences for each outcome. Statistical 
heterogeneity and publication bias were assessed using standard methods. 
Eligibility: Observational or randomized studies comparing survival and/or neurologic outcomes in adults aged 18 years 
or greater resuscitated from out-of-hospital cardiac arrest receiving IH via IVTM versus SCM were eligible for inclusion.  
Results: In total, 12 studies met inclusion criteria. These enrolled 1,573 patients who received IVTM; and 4,008 who 
received SCM. Survival was 55.0% in the IVTM group and 51.2% in the SCM group [pooled risk difference 2% (95% CI -
1%, 5%)]. Good neurological outcome was achieved in 40.9% in the IVTM and 29.5% in the surface group [pooled risk 
difference 5% (95% CI 2%, 8%)]. There was a 6% (95% CI 11%, 2%) lower risk of arrhythmia with use of IVTM and 15% 
(95% CI 22%, 7%) decreased risk of overcooling with use of IVTM versus SCM. There was no significant difference in 
other evaluated adverse events between groups.  
Conclusions:  IVTM was associated with improved neurological outcomes vs. SCM among survivors resuscitated 
following cardiac arrest. These results may have implications for care of patients in the emergency department and 














   Out-of-hospital cardiac arrest (OHCA) affects more than 400,000 individuals in the United States (US)(1) and 624,000 
individuals in Europe(Extrapolated from (2)) annually. Of these, nearly 90% die. Timely restoration of blood flow after the onset 
of cardiac arrest (CA) is critical to survival but the act of restoring flow is associated with cell injury, termed reperfusion 
injury.(3) Studies in animal models of CA demonstrated that mild therapeutic hypothermia, also referred to as induced 
hypothermia (IH) or targeted temperature management (TTM), reduces the inflammation and other harmful processes 
that occur immediately following reperfusion.(4-8)  Also, briefer time from the onset of arrest or initiation of therapeutic 
reduction of core body temperature to achieving moderate hypothermia is associated with significantly better 
outcome.(5, 9-12) In humans resuscitated from CA, briefer time to target temperature appears to be associated with better 
survival.(13-15) Two randomized trials have demonstrated that IH improves outcomes in comatose patients resuscitated 
from cardiac arrest, (16, 17) and mild therapeutic hypothermia between 32C and 36C is currently recommended by 
evidence-based practice guidelines for use in post-cardiac arrest care.(18-20) However, the optimal dose, duration and 
method for IH or TTM have not been fully determined.(21) 
   Multiple methods of IH are in clinical use in patients resuscitated from CA. Intravascular temperature management 
(IVTM), also sometimes referred to as endovascular temperature management, requires insertion of catheters into a large 
vein. Current commercially available catheters have multiple balloons on their external surface that provide a large 
surface area in contact with the patient’s blood. A console is used to circulate chilled saline in a closed loop, and heat 
exchange occurs between the surface of the balloons and the blood so as to induce and maintain IH. Surface cooling 
methods (SCM) require application of ice packs, cooling blankets or gel-adhesive pads to one or more areas of skin so as 
to induce and maintain IH. Each method has differing capabilities of extracting heat, which translate to different rates of 
achieving the intended target temperature. Methods of IH may also differ in their ability to maintain a consistent target 
temperature as well as to control the rewarming phase at the completion of the IH protocol.(22) The different methods of IH 
may also have distinct types and rates of adverse events. Small randomized trials have compared temperature control 
and outcomes in patients who received IH via IVTM vs SCM.(23-25) However, these trials lacked sufficient power to detect a 
small but potentially important difference in outcomes. To date, the effectiveness and safety of IVTM vs. SCM of IH in this 
high-impact population is incompletely defined. Therefore, we conducted a systematic review and meta-analysis to assess 
the effectiveness and safety of IVTM vs. SCM of IH in patients resuscitated from CA. We hypothesized that IVTM would 













   The methods of this review were registered prospectively (PROSPERO 2018 CRD42018112541).(26) A Boolean search 
strategy was applied to the PubMed database (See Online Supplement). In response to a request by a peer-reviewer, this 
was also applied to the Embase and Cochrane systematic reviews databases. This was supplemented by application of the 
Cochrane sensitivity- and precision-maximizing search strategy for randomized controlled trials, and modified for clinical 
studies of hypothermia devices rather than drugs.(27) 
    Included were observational or interventional studies that described use of IVTM and SCM of IH in adults aged 18 years or 
greater who were resuscitated from CA, and that reported survival and/or neurologic outcomes for both IVTM and SCM 
groups. Studies that described only IVTM or SCM without a comparison group were not included. If a study described use of 
multiple means of achieving IH (IVTM or SCM), these data were aggregated prior to inclusion in the systematic review. 
   Unique citations were reviewed to confirm eligibility by two individuals (GN, TV, EB), and relevant data extracted (GN, EB). 
The primary author of each included study was asked to confirm that the data had been extracted correctly. The primary 
author for one study was unable to do so,(28) so the data extracted for that study were confirmed by a second a member of the 
review team (EB). Differences in either study eligibility or data abstraction were resolved by consensus. The methodological 
quality of included observational studies was assessed independently by two individuals (GN, EB) with differences resolved by 
consensus using the Newcastle-Ottawa Quality Assessment form.(29) This is scored by a star system along the domains of 
representativeness of the groups, comparability of the groups and outcomes assessment, with a higher star score indicating 
better quality. Included randomized trials were evaluated in a similar manner using the Cochrane Collaboration’s risk of bias 
tool.(30) This includes seven domains of potential bias and is scored as low, high or uncertain risk of bias.   
   The primary outcome evaluated by this review was survival to hospital discharge. If vital status at discharge was not 
available, we substituted survival to 28 or 30 days or end of study follow-up. A key secondary outcome was good neurologic 
outcome at discharge (or 28 or 30 days or end of study follow-up). Good neurologic outcome was defined as Cerebral 
Performance Category 1 or 2 or modified Rankin score less than or equal to 3. Adverse events of interest included: shivering, 
temperature overcooling, local or skin injury, deep venous thrombosis (DVT), serious bleeding requiring transfusion, 
arrhythmias, pneumonia or sepsis (see Online Supplement for definitions). We sought to abstract sufficient information to be 
able to stratify outcomes by first recorded rhythm. If relevant data were not included in the primary publication, we contacted 
the primary author to request that they provide the missing information.  
   Results were summarized qualitatively and quantitatively by using standard meta-analytic techniques.(31) Analyses were 
performed for the overall results as well as grouped by randomized vs. observational design. Statistical heterogeneity was 
assessed using tau2, inconsistency index I2 and a test of heterogeneity with the related p value. A random effects model 












prospectively registered systematic review protocol were performed. Additionally, rate of arrhythmia in IVTM vs SCM was 
included as a post-hoc analysis. Funnel plots were used to visually check for possible selection or publication bias in 
combination with a test for funnel plot asymmetry based on a linear weighted regression. Secondary analysis used a fixed 
effects model (Mantel-Haenszel) to calculate pooled risk differences for survival and neurologic outcome. The level of 
statistical significance was set a priori at alpha = 0.05. Meta-analysis was performed by using jamovi (Version 0.9, retrieved 
from https://www.jamovi.org) with its ‘major’ package. This was supplemented by using R (Version 3.5.0, retrieved from 
https://www.r-project.org/) with its ‘meta’ package.  
Results 
Literature Search 
  The results of the literature search are summarized in Figure 1. On May 27, 2019, 244 unique candidate citations were 
identified by the search strategy. Four additional candidate citations were identified by the authors of this meta-analysis 
based on their prior knowledge of the literature.(22, 24, 32, 33)  Of these 248 citations, 15 studies were identified as being 
eligible for inclusion. After full text review of each eligible article, three studies were excluded. One evaluated use of IH in 
patients with multiple disorders including but not limited to CA.(34) Another applied fever control methods but not active IH 
to patients who did not receive IVTM.(35) Another did not disaggregate outcomes by IVTM vs. SCM.(36) Twelve studies 
(overall n=5,581 patients) were included in the meta-analysis.   
Included Studies 
   The characteristics of included studies and their enrolled patients and outcomes are summarized in Table 1. Three 
studies were randomized trials;(23-25) four were prospective cohort studies;(22, 28, 32, 33) and three were retrospective case-
control studies.(37-39) Two were secondary analyses of randomized trials: one compared two target temperature ranges 
and another compared two protocols for duration of IH in patients resuscitated from CA.(40,41) Note that we considered 
outcomes in each temperature range and IH duration in these articles separately. All studies enrolled patients with OHCA; 
some also enrolled patients with in-hospital CA. Methodological quality was rated as moderate among included 
observational studies (Online Supplement). The risk of bias was rated as moderate among included trials. 
   The majority of included studies originated from outside the US. The SCM of IH that were used in each study varied, 
and consisted of ice packs, fans, tents, non-adherent cooling blankets or gel adhesive cooling pads. Some also 
administered chilled fluids intravenously. The majority of included studies used a target temperature of 32-34 C or less, 
but two randomized trials used a target temperature of 36 C.(24, 40) One cohort study used target temperatures of 32, 33, 
34 or 35 C, depending on patient characteristics and provider preference.(22) The age and gender distribution of enrolled 












was shockable. Insufficient information was available about patient characteristics, EMS processes of care, time from 
activation of emergency medical services to initiation of hypothermia or achievement of target temperature, use of 
sedation or paralytics to reduce shivering, or rate of rewarming to pool these data to make any inferences about the 
relationship between these factors and outcomes. As well, there was insufficient information regarding the precision and 
variability of induced hypothermia in each study to assess the association between these factors and patient outcomes.   
1,573 patients (28%) received IVTM; 4,008 received SCM (71.8%). Survival data were available for all patients included. 
Neurological outcomes data were available for 1,514 patients in the IVTM group and 3,962 in the SCM group. Survival 
was 55.0% in the IVTM group and 51.2% in the SCM group. Good neurological outcome was achieved in 40.9% in the 
IVTM and 29.5% in the SCM group. 
Pooled Effects 
   Pooled data from included studies demonstrated that use of IVTM was associated with an absolute 2% (95% CI -1%, 
5%) greater chance of survival as compared to SCM.  There was an absolute 5% (95% CI 2%, 8%) greater chance of 
good neurological outcome associated with use of IVTM compared to SCM. These results are summarized in Figure 2. 
   There was no significant statistical heterogeneity among studies that reported survival data (p value=0.74) or in those that 
reported the incidence of good neurological outcome (p value=0.82). There was no evidence of publication bias among 
studies that reported survival data (regression test for funnel plot asymmetry p value=0.24) or in those that reported the 
incidence of good neurological outcome (regression test for funnel plot asymmetry p value=0.94). 
    Secondary analysis using a fixed effects model demonstrated that use of IVTM was associated with an absolute 2% 
(95% CI -1%, 5%) greater chance of survival as compared to SCM (Online Supplement).  There was an absolute 5% 
(95% CI 2%, 8%) greater chance of good neurological outcome associated with use of IVTM compared to SCM using this 
method of analysis as well. 
   There was a 6% (95% CI 11%, 2%) lower risk of arrhythmia with IVTM versus SCM and an 15% decreased risk of 
temperature overcooling with use of IVTM versus SCM (95% CI 22%, 7%) (See Online Supplement). There was no 
significant difference between groups with regards to the risk of shivering, skin injury, clinically significant bleeding, DVT, 
pneumonia or sepsis.  
   There was no evidence of a differential effect of IVTM upon survival to discharge or neurological outcome at discharge 
in studies that employed a randomized vs. observational design. There were insufficient data available to evaluate for a 
differential effect of IVTM as compared with SCM in studies of US vs. ex-US origin, first recorded rhythm, no-flow time 
(EMS call to sustained restoration of flow in minutes), time to target temperature (EMS call to target temperature in minutes), 












   There were insufficient data available for a post hoc analysis to evaluate the differential effect of IVTM as compared to 
SCM of IH with target temperature 34C or less vs. 36 C. 
Discussion 
   This systematic review of randomized trials and observational studies from multiple geographically separate locations 
reported over a decade-long period suggested that IH using IVTM as compared to SCM is associated with a significant 
and important beneficial effect on neurological outcome in patients resuscitated from OHCA.  Treatment of 20 (95% CI 13, 
50) patients with IVTM as compared to SCM was associated with one more individual with good neurologic outcome. As 
well, there was a significant decrease in the rate of arrhythmias and of temperature overcooling with use of IVTM as 
compared to SCM. There was no significant difference in the rate of shivering, skin injury, serious bleeding, DVT, 
pneumonia, or sepsis between IVTM and SCM. Several of the latter comparisons were limited by sparse data. The overall 
quality of the included studies was moderate. There was no evidence of statistical heterogeneity or publication bias.  
   An insufficient number of patients resuscitated from CA (overall n=352) have been randomized to IH vs. normothermia 
to have sufficient power to detect small but important differences in outcome between the two interventions.(16, 17) Due to 
lack of clinicians’ equipoise,(18-20) a US-based trial of IH vs. normothermia is likely infeasible. In the absence of a larger 
amount of additional randomized evidence of the effect of IH vs. normothermia in patients resuscitated from CA, this 
systematic review and meta-analysis could inform ongoing debate among providers about whether IH improves outcomes 
compared to normothermia in patients resuscitated from CA. Prior randomized trials of IH as compared to normothermia 
in patients with CA yielded mixed results. Two trials that monitored adherence to IH and achieved target temperature 
quickly observed improved outcomes with IH vs. normothermia.(16, 17) In contrast, IH without early achievement of target 
temperature was not associated with benefit.(42, 43) These discordant results may be due in part to variation in the time to 
achieving target temperature between trials or drugs used to reduce shivering.(3)  
  Due to discordant information about whether a target temperature of 34C or less is necessary, many providers have 
adopted target temperature of 36C. However, multiple large retrospective analyses of data collected for reasons 
unrelated to IH (overall n=100,085) suggest that among patients resuscitated from CA, a target temperature of 36C is 
associated with worse outcomes as compared to a target of 34 C or less.(44-46) Although the present analysis had limited 
power to detect differences in outcome between different target temperatures, our observation that IVTM is associated 
with better neurological outcome than SCM of IH could provide indirect evidence that there is an association between 
active use of IH as opposed to normothermia and better outcomes in patients resuscitated from OHCA. 
   This study has some limitations. First, we considered only citations written in English. This reduced the number of 












larger in non-English as opposed to English studies,(47) and restriction to English-language studies is unlikely to bias the 
results of a systematic review.(48) 
   Second, our strict eligibility criteria reduced the overall number of studies and patients included in our systematic review. 
While the present analysis was undergoing revision after its initial peer review, another systematic review the effect of 
different methods of IH was published.49 The latter included 22 studies (overall n=8,027). Of these, one study compared 
IVTM vs SCM and reported survival to discharge but not neurologic outcome in the English language (overall n=69).50 A 
post hoc analysis including this additional study did not suggest that IVTM significantly improved survival vs. SCM (details 
available from authors). In contrast to the other systematic review, we separated IVTM and SCM groups in trials of mild 
vs. moderate IH as well as brief vs. prolonged IH, and emphasized random effects rather than fixed effects analysis. Thus 
our methods avoid underestimating uncertainty (i.e., had wider confidence intervals in effect estimates) than the other 
analysis. As well, we evaluated differences in adverse events as well as effectiveness outcomes with IVTM vs. surface. 
Thus we believe that the results of the present study are more robust than those of the other systematic review. 
   Third, the majority of patients included in this analysis were enrolled in observational rather than randomized studies. As 
such, we can infer association between use of IH and outcomes after OHCA, rather than causation. However, a subgroup 
analysis of the results of data derived from randomized studies did not demonstrate a significant difference in effects 
found for either neurological outcomes or overall survival.  
   Fourth, multiple factors are associated with outcome after OHCA. There was insufficient information about time to target 
temperature in each study to be able to relate it to outcome. The SCM employed in studies included in this analysis were 
heterogeneous, but we were unable compare the effect of specific SCM.  In addition to method of IH, important prognostic 
factors may include initial rhythm (i.e., ventricular fibrillation versus pulseless electrical activity or asystole),(51) site of 
initiation of IH (pre-hospital or emergency department),(52-55) duration of IH,(52) and concurrent medications to reduce 
shivering and sedation. . Multi-center observational studies and a systematic review suggest that the outcomes of patients 
resuscitated from OHCA are associated with the components of care administered after transportation to a receiving 
hospital.(53-56) These include emergency coronary angiography and selective percutaneous coronary intervention, as well 
as deferred prognostic assessment and withdrawal of life-sustaining treatment in addition to IH. Included articles lacked 
information regarding these components of resuscitation after OHCA so we cannot draw conclusions about their relative 
contributions to patient outcomes based on the results of this systematic review and meta-analysis. 
   Fourth, there was a significant difference in neurologic outcome but not survival with IVTM vs. SCM. It is possible that 
the latter may be attributable to a lack of survival benefit from IH. Alternatively, the lack of significant survival benefit may 












not try to mitigate the competing risk of premature prognosis assessment and withdrawal of life sustaining treatments 
upon survival.(57) 
   This study has some strengths. First, to the best of our knowledge, the overall sample size of the present study is larger 
than any prior controlled assessments of use of IH in individual patients with CA. This yields more precise effect estimates 
than previous studies. Second, treatment effects were pooled using a random-effects statistical model. Meta-analyses 
commonly use a fixed effect or a random-effects model. The former assumes all studies are estimating the same (i.e., 
fixed) treatment effect, whereas the latter allows for differences in the treatment effect from study to study.(58) Although 
both methods are criticized,(59) random-effects models are less likely to overstate certainty (i.e., underestimate confidence 
interval around the pooled treatment effect). 
   Third, included studies were widely separated by geography, time and method of IH. Ordinarily, this would be expected 
to attenuate differences between treatment and outcome. Instead, we observed significant differences. We therefore infer 
that the observed differences are likely generalizable to other settings.   
Conclusions  
 
  Temperature management following CA using IVTM as compared to SCM is associated with a significant and important 
beneficial effect on neurological outcome but not on overall survival. Our findings suggest that use of IVTM may be 
preferable to use of SCM to reduce morbidity in this population. Future research on induced hypothermia after cardiac 
arrest should report cooling method(s) used, characteristics of cooling (including time to target temperature, temperature 
precision and duration of cooling) as well as the characteristics of EMS and in-hospital care. 
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Figure 2: Random-Effects Forrest Plots for Risk Difference in Survival and Good Neurologic Outcome 
A) Survival 
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*Defined as < 32 C 
†Defined as 32.5 to 33.5 C 
®Included VT and VF; #to < 34 C, $ to < 30 C; %recurrent cardiac arrest, ^arrhythmia requiring therapy; &to < 32 C 












ß From first CPR 
∂ In first 24 h  
ƒ 28 days  
©Call to target temp 
§Defined as from beginning of cooling to beginning of rewarming 
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